Custom Antibody Drug Conjugate Development, Testing and Validation
Services We Offer
- Bioconjugation linker development to optimise your ADC improving hydrophobicity, Drug to Antibody Ratio (DAR) and Pharmacokinetics (PK)
- Custom Linker manufacture to tailor ADCs to your targets, ensuring linker stability, payload potency, and therapeutic stability through further testing
- Optimisation of Linker-Payload and Conjugate using advanced technologies (Site-specific conjugation, Next-Generation linker, and Multifunctional conjugation platforms)
- Assessment and testing of Preliminary Analytics: Assess binding affinity, target specificity, and stability.
- Assess the internalisation of antibody-drug conjugates (ADCs), by measuring the internalisation through pH-sensitive and fluorophore-quenching assays, including quantitative insights on ADC uptake into lysosomes.
- Other preliminary assessment includes plasma stability tests, lysosomal payload release assessments, and cytotoxicity assays, ensuring ADCs perform reliably in preclinical studies
Key Benefits
- Experienced Technical Team with optimised assays helps to accelerate the research timelines
- Highly validated before any preclinical approach or studies conducted
- Reduces Technical complexity which is greater challenge during early-stage ADC development
- Increase the likelihood of therapeutic success with precise matching of antibody, linker and payload to target antigen or disease model
- Reproducibility and Validation requirements are omitted as ADCs undergo rigorous analytical and biological characterisation
Custom Antibody Drug Conjugate Form
To streamline the process and ensure we understand your specific requirements effectively, please fill out this Custom Antibody Drug Conjugate Form:
